Global HER-2 Positive Breast Cancer Market 2015-2019
Single User License - $3000 Site User License - $3500 Corporate User License - $4500 Publication Date - Mar 2015 Pages - 123 To know more details, email to debora@reportstack.com
Contact: debora@reportstack.com Reportstack Market Research
Summary ď ś Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells.
Contact: debora@reportstack.com Reportstack Market Research
Key Regions • Americas • APAC • EMEA
Contact: debora@reportstack.com Reportstack Market Research
Key vendors
• Celgene • F. Hoffmann-La Roche • GlaxoSmithKline • Novartis • Sanofi
Contact: debora@reportstack.com Reportstack Market Research
Companies Mentioned • • • • • • • • • • • • • • •
Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, Sanofi, Actavis, Array BioPharma, Biocad, Biocon, Boehringer Ingelheim, Bristol-Myers Squibb , Celltrion, Chugai Pharmaceutical, DARA BioSciences, EddingPharm , etc
Contact: debora@reportstack.com Reportstack Market Research
If you are interested...
Contact : Debora White Email: debora@reportstack.com Ph:+1-888-789-6604 http://www.reportstack.com
Contact: debora@reportstack.com Reportstack Market Research